Your browser doesn't support javascript.
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.
Walls, Alexandra C; Sprouse, Kaitlin R; Bowen, John E; Joshi, Anshu; Franko, Nicholas; Navarro, Mary Jane; Stewart, Cameron; Cameroni, Elisabetta; McCallum, Matthew; Goecker, Erin A; Degli-Angeli, Emily J; Logue, Jenni; Greninger, Alex; Corti, Davide; Chu, Helen Y; Veesler, David.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: acwalls@uw.edu.
  • Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Joshi A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Franko N; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Navarro MJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Stewart C; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Cameroni E; Humabs Biomed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Goecker EA; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
  • Degli-Angeli EJ; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
  • Logue J; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Greninger A; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
  • Corti D; Humabs Biomed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu.
Cell ; 185(5): 872-880.e3, 2022 03 03.
Article in English | MEDLINE | ID: covidwho-1699915
ABSTRACT
Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Cell Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Cell Year: 2022 Document Type: Article